Quantitative assessment of minimal residual disease in acute myeloid leukemia carrying nucleophosmin (NPM1) gene mutations
Open Access
- 16 March 2006
- journal article
- research article
- Published by Springer Science and Business Media LLC in Leukemia
- Vol. 20 (6), 1103-1108
- https://doi.org/10.1038/sj.leu.2404149
Abstract
No abstract availableKeywords
This publication has 18 references indexed in Scilit:
- Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: interaction with other gene mutationsBlood, 2005
- Prevalence, clinical profile, and prognosis of NPM mutations in AML with normal karyotypeBlood, 2005
- Nucleophosmin mutations in childhood acute myelogenous leukemia with normal karyotypeBlood, 2005
- Development of a quantitative-PCR method for specific FLT3/ITD monitoring in acute myeloid leukemiaLeukemia, 2004
- Minimal residual disease monitoring by flow cytometryBest Practice & Research Clinical Haematology, 2003
- Prognostic Value of Minimal Residual Disease Quantification by Real-Time Reverse Transcriptase Polymerase Chain Reaction in Patients With Core Binding Factor LeukemiasJournal of Clinical Oncology, 2003
- Detection of minimal residual disease in hematologic malignancies by real-time quantitative PCR: principles, approaches, and laboratory aspectsLeukemia, 2003
- Quantitative assessment of WT1 expression by real time quantitative PCR may be a useful tool for monitoring minimal residual disease in acute leukemia patientsLeukemia, 2002
- Assessment of minimal residual disease (MRD) in CBFbeta/MYH11-positive acute myeloid leukemias by qualitative and quantitative RT-PCR amplification of fusion transcriptsLeukemia, 2002
- Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhoodThe Lancet, 1998